# AI and automation in antibody discovery

> Live situation record from CLSTR: https://clstr.news/situations/ai-and-automation-in-antibody-discovery
> Updated: 2026-10-07T17:35:33.000Z. Sources: 5. Developments: 2.

The biotechnology sector is increasingly integrating artificial intelligence and automation to enhance antibody discovery and development. 

In late September 2026, Ginkgo Datapoints and Apheris launched the Antibody Developability Consortium. This industry collaboration, involving members such as AbbVie, argenx, Lundbeck, and Takeda, aims to create a standardized dataset of approximately 10,000 antibodies. By utilizing privacy-preserving federated data networks, the consortium seeks to build more robust AI models to better predict manufacturability and developability risks in antibody candidates.

Following this, Danaher Corporation announced plans to launch an AI-powered autonomous laboratory by early 2027. Operating through its subsidiary Abcam, the facility will employ a ‘design-make-test-learn’ loop that combines AI-driven design with robotic execution. This automated workflow is intended to significantly accelerate affinity reagent discovery and increase annual output.

## Timeline

### 2026-10-07: Danaher to launch AI-powered autonomous antibody lab in 2027

Danaher Corporation plans to open an AI-driven autonomous laboratory by 2027 to accelerate antibody discovery through a continuous robotic ‘design-make-test-learn’ cycle.

2 sources. https://clstr.news/cluster/danaher-to-launch-ai-powered-autonomous-antibody-lab-in-2027

### 2026-09-29: Antibody Developability Consortium launched to advance AI-powered drug discovery

Ginkgo Datapoints and Apheris have launched the Antibody Developability Consortium to build a massive AI-ready dataset for predicting antibody manufacturability.

3 sources. https://clstr.news/cluster/antibody-developability-consortium-launched-to-advance-ai-powered-drug-discovery

---
Cite as: AI and automation in antibody discovery. CLSTR, https://clstr.news/situations/ai-and-automation-in-antibody-discovery
